Certolizumab pegol

Drug Profile

Certolizumab pegol

Alternative Names: CDP-870; Cimzia; CIMZIA AutoClicks Prefilled Pen; CZP; PHA-738144; Simziya

Latest Information Update: 14 Mar 2017

Price : $50

At a glance

  • Originator UCB
  • Developer Astellas Pharma; Dermira; UCB; University of Southampton
  • Class Anti-inflammatories; Antirheumatics; Fab fragments; Monoclonal antibodies; Polyethylene glycols
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Spondylitis
  • Phase III Interstitial cystitis; Juvenile rheumatoid arthritis; Plaque psoriasis
  • Discontinued Cognition disorders

Most Recent Events

  • 04 Mar 2017 Updated efficacy and adverse events data from the phase III CIMPASI-1 and CIMPASI-2 trials in Plaque psoriasis released by UCB and Dermira
  • 04 Mar 2017 Updated pharmacodynamics data from the phase III RAPID™-PsA trial in Psoriatic arthritis released by UCB and Dermira
  • 28 Feb 2017 Dermira and UCB announces intention to submit sBLA to US FDA for moderate-to-severe chronic plaque psoriasis in the third quarter of 2017 (Dermira 10-K, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top